Is Genmab A/S halal to invest in?

According to Musaffa's Shariah screening methodology, Genmab A/S (GMAB.CO) is currently classified as NOT HALAL as of February 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Genmab A/S a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Genmab A/S using these criteria to determine its compliance status.

Can Muslims buy shares of Genmab A/S?

Muslim investors may consider investing in Genmab A/S if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Genmab A/S classified as NOT HALAL?

Musaffa determines the Shariah status of Genmab A/S by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Genmab A/S updated?

The Shariah compliance status of Genmab A/S may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Genmab A/S become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Genmab A/S?

You can check the latest Shariah compliance status of Genmab A/S on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Genmab A/S GMAB.CO

Last Updated: May 13, 12:00 AM·CSE

GMAB.CO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: February 23, 2026

Report Source: 2025 Annual Report

Genmab A/S. Stock Analysis GMAB.CO

Denmark Health Care Large Cap Report: 2025 Annual

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!

Genmab A/S GMAB.CO

NOT HALAL

Genmab A/S. Stock Analysis GMAB.CO

Shariah Compliance Report

Disclaimer